文献速递前列腺癌

低级别前列腺癌主动监测的长期结局:基于人群的标志性分析研究

Long-term Outcomes Following Active Surveillance of Low-grade Prostate Cancer: A Population-based Study Using a Landmark Approach.
PubMed 文献 · J Urol · 2022-12-07

本研究利用加拿大安大略省关联行政数据库,回顾性纳入2002—2014年接受主动监测或初始治疗的低级别前列腺癌患者,以24个月为标志点比较10年与15年结局。队列共21,282例,中位随访9.8年;主动监测与初始治疗相比转移风险更高(HR 1.34,95%CI 1.15-1.57),总死亡风险更高(HR 1.12,95%CI 1.01-1.24),前列腺癌特异性死亡风险更高(HR 1.66,95%CI 1.15-2.39)。

要点

  • 主动监测10年仍继续监测率为39%,无转移生存率94.2%,总生存率88.7%,癌症特异性生存率98.1%
  • 调整模型中主动监测较初始治疗转移风险升高(HR 1.34,95%CI 1.15-1.57)
  • 主动监测10年癌症特异性生存略差(差1%),需与过度治疗的已知危害权衡

核心结论

  • 在低级别前列腺癌男性的大样本基于人群长期结局研究中,主动监测与良好的长期无转移生存和总生存相关。
  • 但长期癌症特异性生存略差(主动监测10年差1%),这必须与过度治疗的已知危害相权衡。

研究设计与样本

  • 回顾性、基于人群的研究,使用加拿大安大略省关联行政数据库,纳入2002—2014年接受主动监测或初始治疗的低级别前列腺癌患者。
  • 队列共21,282例低级别前列腺癌患者,中位随访9.8年;主要分析选择24个月为标志点。
  • 长期结局采用多因素比例风险模型和基于倾向评分的方法分析,另用7,525对倾向匹配进行分析。

主要发现

  • 10年随访时仍继续主动监测的生存率为39%,无转移生存率94.2%,总生存率88.7%,癌症特异性生存率98.1%。
  • 调整模型中,与初始治疗相比,主动监测与更高的转移风险相关(HR 1.34,95%CI 1.15-1.57)。
  • 调整模型中,与初始治疗相比,主动监测与更高的总死亡风险相关(HR 1.12,95%CI 1.01-1.24)。
  • 调整模型中,与初始治疗相比,主动监测与更高的前列腺癌特异性死亡风险相关(HR 1.66,95%CI 1.15-2.39)。
  • 使用7,525对倾向匹配的生存分析在无转移生存、总生存和癌症特异性生存方面与主要分析一致。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Active surveillance is widely used to manage low-risk prostate cancer, but population-level long-term outcomes are limited. Our objective was to determine long-term population-level oncological outcomes in active surveillance patients. A secondary objective examined the active surveillance discontinuation rate. MATERIALS AND METHODS: In this retrospective, population-based study using linked administrative databases from Ontario, Canada, we identified low-grade prostate cancer patients managed with active surveillance or initial treatment between 2002-2014. The 10- and 15-year metastasis-free survival, overall survival, and cancer-specific survival were compared between active surveillance and initial treatment. A landmark of 24 months was selected for the primary analysis. Long-term outcomes were examined using multivariable proportional hazards models and a propensity-based approach. RESULTS: The cohort consisted of 21,282 low-grade prostate cancer patients with a median follow-up of 9.8 years. At 10-year follow-up the survival rate of remaining on active surveillance was 39%, metastasis-free survival was 94.2%, overall survival 88.7%, and cancer-specific survival 98.1%. In adjusted models active surveillance was associated with higher risk of metastasis (HR 1.34, 95%CI 1.15-1.57), overall mortality (HR 1.12, 95%CI 1.01-1.24), and prostate cancer-specific mortality (HR 1.66, 95%CI 1.15-2.39) compared to initial treatment. Survival analysis using 7,525 propensity-matched pairs was consistent with the primary analysis for metastasis-free survival, overall survival and cancer-specific survival. CONCLUSIONS: In this large population-based study of long-term outcomes in men with low-grade prostate cancer, active surveillance is associated with excellent long-term metastasis-free survival and overall survival. However, long-term cancer-specific survival was slightly inferior (1% worse at 10 years with active surveillance), and this must be balanced against known harms of overtreatment.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Timilshina N, Alibhai SMH, Tomlinson G, et al. Long-term Outcomes Following Active Surveillance of Low-grade Prostate Cancer: A Population-based Study Using a Landmark Approach. J Urol. 2022. PMID: 36475730. doi:10.1097/JU.0000000000003097

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。